<a href="https://laohu8.com/S/MRNA">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada
CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.